Connect with us

Featured

3 Tech Stocks To Watch That Released Big News This Month

A. Lawrence

Published

on

penny stocks news

Investing in stocks can lead to enormous gains in a short span of time, but at the same time, it is not easy to accomplish that. The simple reason is that there are plenty of such stocks in the market. An investor needs to do plenty of research in order to pick the right stocks. The wrong pick can easily lead to losses.

Hence, research and having an idea about the market is paramount for success with any stock. Other things to keep in mind are major corporate events. This poses two angles for investors to think about.

Is the news good or is it bad? Good news, of course, can trigger bullish momentum while bad news could spark a huge sell-off in stocks. On that note, here is a look at 3 tech stocks that may be worth a closer look after the latest round of news.

Penny Stocks In the News #1 Liberty Defense (TSX:SCAN.V0 (OTC:LDDFF)

Liberty provides security solutions for concealed weapon detection in high volume foot traffic areas and has secured an exclusive license from Massachusetts Institute of Technology. Liberty Defense (TSX: SCAN.V) (OTC: LDDFF)  also has a technology transfer agreement, for patents related to active 3D radar imaging technology that are packaged into its HEXWAVE product.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) has a technology that could disrupt this multi-billion-dollar industry for the better. The company‘s  HEXWAVE is a next-generation high-tech security scanning system that will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively. It’s gained notoriety from countless media outlets and Liberty has been able to greatly capitalize by closing on several beta testing agreements.

What Happened In The News?

For Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) , 2 milestones have happened within the 3 weeks. First, Laurentian Bank Securities Inc. has initiated coverage of the Company. Additionally, Liberty has signed a collaboration agreement to beta test its flagship product, HEXWAVE, with the Maryland Stadium Authority, the unit of state government that owns and manages the sporting venues at Camden Yards in the city of Baltimore. This is in addition to the growing list of previous beta test deals in place.

Penny Stocks In the News #2 GameStop Corp (GME)

GameStop Corp. (GME Stock Report) isn’t the pure play tech stock but does deal directly with one of the most popular forms of tech that millennials love; gaming. The video game retailer has had a bit of a rollercoaster ride over the past few weeks and that has reflected on its stock price as well.

The company had earlier announced that it was going to close as many as 200 retail stores until Christmas. Although that is a positive development for investors, there was another reason for the 6.6% rise in the stock price on Monday.

GME stock price

Placer.ai, a company that is involved in analyzing consumer foot traffic, stated in a note that the traffic to the company stores in July and August are going to rise. The firm has projected a 3.8% year on year rise in Q3 2019. That is believed to be the reason behind the rise in the stock yesterday.

What Happened In The News?

Wedbush analyst Michael Pachter has a contrarian bullish view on GameStop, and said in a note that he expects shares to trade at a compressed EPS multiple until the company can slow the rate of decline in its core video game business.

“We continue to believe that GameStop is an attractive investment. The company expects to generate over $200 million in free cash flow this year, and we think ongoing sales of the Switch Lite, a solid release schedule next year and the launch of next-generation consoles late in the year can keep GameStop generating $200 million or more in free cash flow annually for years to come,” the analyst said.

Penny Stocks In the News #3 Nio Inc (NIO)

On the other hand, Chinese electric vehicle manufacturer Nio Inc – ADR (NIO Stock Report) has had a pretty disappointing year so far. On Tuesday, the stock experienced another steep decline. The stock declined by as much as 10% on Monday as the selloff began. NIO stock has had a remarkably poor year so far and is down by as much as 56%. However, it is important to note that if the company manages to deliver decent results then the stock could climb again.

NIO stock price

Tuesday saw the company’s stock decline further. News of a capital raise shook the market. There are still several unknowns about the future of the company and a lot of that has to do with the competitive landscape in China. This may be one of the penny stocks to watch later on if or when it can firmly turn around its operations. Near term, however, there’s no clear cut direction.

What Happened In The News?

Shares of Nio tumbled Tuesday after the Chinese electric-car maker reported second-quarter losses that neared half a billion dollars. Nio stock, down 67% in 2019 through Monday’s close, was recently off 23% to $2.10 as the company compounded concerns surrounding its losses by canceling its customary quarterly conference call with management.

The company posted a second-quarter net loss of $479 million, or 47 cents a share, on revenue of $206 million. Its gross margins, which are negative, widened substantially from the first quarter, largely because of a recall.


tech stocks to watch august
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019NOW EXTENDED TO 10/31/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For previous compensation see our FULL DISCLAIMER HERE

Continue Reading
Click to comment

Biotechnology

3 Penny Stocks Looking To Change The Biotech Industry

Jon Phillip

Published

on

biotechnology stocks

The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.

Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

GT Biopharma Inc. (GTBP)

One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.

biotechnology stocks to buy now

So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.

TriKE Therapy

One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.

“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.

Conatus Pharmaceuticals Inc. (CNAT)

This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.

biotechnology stocks to watch

In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.

Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.

Nuvectra Corporation (NVTR)

To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.

breakthrough biotech stocks to watch

Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.

Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

biotechnology stocks

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here

Continue Reading

Biotechnology

Are These Biotech Names On Your October Watch List?

Joe Samuel

Published

on

biotech stock price

Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.

Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

best biotechnology stocks to buy now

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.

Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)                                           

The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.

The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.

Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.

Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)

The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.

The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.

list of healthcare stocks to watch

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.

Continue Reading

Featured

Stock Price Newsletter – October 18, 2019

Joe Samuel

Published

on

Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch

The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.

Click Here


In Case You Missed It: Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient

Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.

Read More Here


These Healthcare & Biotech Stocks Deserve Your Attention This Month

The positive results provided a break for the sector. Furthermore, healthcare stocks have risen by 5.7% this year. The entire index has seen a nearly 20 percent gain, according to The Wall Street Journal. With this in mind, healthcare and biotechnology stocks are in focus this month.

Continue Reading


top biotechnology stocks to watch today

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com